Sirolimus Is Associated With Veno-Occlusive Disease of the Liver After Myeloablative Allogeneic Stem Cell Transplantation
12/2008
Journal Article
Authors:
Cutler, C.;
Stevenson, K.;
Kim, H.T.;
Richardson, P.;
Ho, V.T.;
Linden, E.;
Revta, C.;
Ebert, R.;
Warren, D.;
Choi, S.;
Koreth, J.;
Armand, P.;
Alyea, E.;
Carter, S.;
Horowitz, M.;
Antin, J.H.;
Soiffer, R.
Secondary:
Blood
Volume:
112
Pagination:
4425-4431
URL:
http://www.ncbi.nlm.nih.gov/pubmed/18776081
Keywords:
Drug Combinations; Female; Graft vs Host Disease/prevention & control; Hematopoietic Stem Cell Transplantation*/methods; Hepatic Veno-Occlusive Disease/chemically induced*; Hepatic Veno-Occlusive Disease/epidemiology; Humans; Immunosuppressive Agents
Abstract:
{Sirolimus is an effective agent used in graft-versus-host disease (GVHD) prophylaxis after allogeneic transplantation. It also has antiproliferative effects on vascular endothelium when used to coat coronary artery stents. We noted an excess of veno-occlusive disease (VOD) in a clinical trial, and retrospectively reviewed the records of 488 patients to determine the association between sirolimus and VOD. When used with cyclophosphamide/total body irradiation (Cy/TBI) conditioning, sirolimus is associated with an increased incidence of VOD (OR 2.35
